May 25, 2026 - ChartAlert®

BOSCHLTD – Bosch Limited – Q4 FY26 Earnings Call – 21-May-26

Bosch’s findings imply topline resilience (8–10% base-case growth) with margin expansion (50bps) hinging on cost controls and content per vehicle, while PAT growth (10–12%) is anchored by structural initiatives but vulnerable to macro shocks.

1–2 minutes

Also see: BOSCHLTD – Bosch Limited – Q4 FY26 Financial Results – 20-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Macro stability persists; crude oil rises 10%, but supply chain agility offsets costs. Flattish volume growth is offset by content per vehicle gains (CAFE Phase 3, ADAS). JV ramps up in FY’28, contributing 2–3% to revenue. Revenue grows 8–10%, EBITDA margins expand 50bps, and PAT grows 10–12%.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Earnings Call – 19-May-26

Zydus Lifesciences’ topline growth hinges on specialty scaling and international momentum, while margins and cash flow are sensitive to US generics competition, acquisition execution, and capex intensity.

1–2 minutes

Also see: ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Management delivers on high-teens revenue growth and >24% EBITDA margins in FY27. US generics decline offset by specialty/international growth, while MedTech/Comfort Click meet guidance. Capex/working capital pressure limits FCF growth, but leverage remains <1x net debt-to-EBITDA. Biosimilar scale-up aligns with FY29–30 timeline.